Nan Fung Trinity HK Ltd. Acquires Shares of 342,885 Bicara Therapeutics Inc. $BCAX

Nan Fung Trinity HK Ltd. bought a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) during the second quarter, HoldingsChannel reports. The fund bought 342,885 shares of the company’s stock, valued at approximately $3,185,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of BCAX. CWM LLC acquired a new stake in shares of Bicara Therapeutics during the first quarter worth about $29,000. New York State Common Retirement Fund purchased a new position in shares of Bicara Therapeutics in the 1st quarter valued at approximately $52,000. Federated Hermes Inc. increased its holdings in shares of Bicara Therapeutics by 50.0% in the first quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock valued at $156,000 after purchasing an additional 4,000 shares during the period. AQR Capital Management LLC purchased a new stake in shares of Bicara Therapeutics during the first quarter worth approximately $248,000. Finally, Rhumbline Advisers lifted its holdings in shares of Bicara Therapeutics by 21.1% during the first quarter. Rhumbline Advisers now owns 23,018 shares of the company’s stock worth $300,000 after purchasing an additional 4,010 shares during the period.

Bicara Therapeutics Stock Up 5.7%

NASDAQ:BCAX opened at $14.73 on Wednesday. The stock has a fifty day simple moving average of $14.75 and a 200-day simple moving average of $12.53. Bicara Therapeutics Inc. has a 52-week low of $7.80 and a 52-week high of $24.15. The company has a market capitalization of $804.41 million, a PE ratio of -6.58 and a beta of -0.76.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Monday, November 10th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.12). As a group, equities analysts anticipate that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Tuesday, October 14th. Piper Sandler began coverage on shares of Bicara Therapeutics in a research note on Monday, August 18th. They set an “overweight” rating and a $36.00 price target on the stock. HC Wainwright cut their price target on shares of Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a report on Friday, August 22nd. Wedbush restated an “outperform” rating and issued a $30.00 price target on shares of Bicara Therapeutics in a research note on Monday. Finally, Wells Fargo & Company raised their target price on Bicara Therapeutics from $8.00 to $11.00 and gave the company an “equal weight” rating in a report on Tuesday. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Bicara Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.67.

Insider Activity

In other Bicara Therapeutics news, CFO Ivan Hyep sold 18,244 shares of the company’s stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $18.22, for a total value of $332,405.68. Following the transaction, the chief financial officer directly owned 145,355 shares in the company, valued at approximately $2,648,368.10. This represents a 11.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Ryan Cohlhepp sold 39,600 shares of Bicara Therapeutics stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $18.06, for a total transaction of $715,176.00. Following the sale, the chief operating officer owned 205,541 shares of the company’s stock, valued at approximately $3,712,070.46. This trade represents a 16.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 146,534 shares of company stock worth $2,682,012.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.